Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.91 -0.5%	$10.08	$6.02 ▼ $11.31	$1.86B	1.04	3.03 million shs	422,725 shs
CLDX Celldex Therapeutics	$22.51 -3.6%	$20.55	$14.40 ▼ $47.00	$1.50B	1.13	959,173 shs	70,313 shs
FOLD Amicus Therapeutics	$6.02 -3.6%	$6.07	$5.51 ▼ $12.65	$1.85B	0.51	3.22 million shs	227,085 shs
MYGN Myriad Genetics	$5.19 -0.7%	$4.90	$3.81 ▼ $29.30	$475.17M	1.91	1.26 million shs	69,767 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	+2.28%	+2.28%	-13.60%	+21.08%	+25.31%
CLDX Celldex Therapeutics	+1.96%	+11.34%	+9.88%	+27.16%	-41.31%
FOLD Amicus Therapeutics	+2.46%	+3.14%	+3.48%	-9.57%	-40.06%
MYGN Myriad Genetics	-2.25%	-1.32%	+3.78%	-34.83%	-80.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.2076 of 5 stars	4.5	1.0	4.2	1.4	1.7	0.6
CLDX Celldex Therapeutics	2.4992 of 5 stars	4.4	1.0	0.0	3.8	0.0	0.0
FOLD Amicus Therapeutics	4.1301 of 5 stars	3.4	1.0	4.3	3.2	0.0	1.9
MYGN Myriad Genetics	4.606 of 5 stars	4.1	4.0	4.1	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	86.38% Upside
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	114.52% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	159.97% Upside
MYGN Myriad Genetics	2.13	Hold	$14.38	175.57% Upside

Current Analyst Ratings Breakdown

Latest MYGN, FOLD, BCRX, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	4.16	N/A	N/A	($2.30) per share	-3.90
CLDX Celldex Therapeutics	$7.02M	220.89	N/A	N/A	$11.26 per share	2.07
FOLD Amicus Therapeutics	$543.14M	3.54	N/A	N/A	$0.65 per share	9.60
MYGN Myriad Genetics	$831.30M	0.58	$0.98 per share	5.34	$7.70 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.50	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	14.51	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$1.12	N/A	N/A	N/A	-12.20%	-4.95%	-3.39%	8/5/2025 (Estimated)

Latest MYGN, FOLD, BCRX, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	MYGN Myriad Genetics	-$0.02	N/A	N/A	N/A	$202.30 million	N/A
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.02	N/A	N/A	N/A	$149.59 million	N/A
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
CLDX Celldex Therapeutics	N/A	21.67	21.67
FOLD Amicus Therapeutics	2.02	3.34	2.47
MYGN Myriad Genetics	0.08	1.90	1.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
CLDX Celldex Therapeutics	N/A
FOLD Amicus Therapeutics	N/A
MYGN Myriad Genetics	99.02%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
CLDX Celldex Therapeutics	4.40%
FOLD Amicus Therapeutics	2.20%
MYGN Myriad Genetics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
MYGN Myriad Genetics	2,700	92.18 million	90.24 million	Optionable

MYGN, FOLD, BCRX, and CLDX Headlines

Recent News About These Companies

Myriad Genetics Earns 2025 Great Place To Work Certification™

1 hour ago | finance.yahoo.com

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Brokerages

July 10, 2025 | marketbeat.com

MYGN Myriad Genetics, Inc. - Seeking Alpha

July 3, 2025 | seekingalpha.com

5 Revealing Analyst Questions From Myriad Genetics’s Q1 Earnings Call

June 27, 2025 | msn.com

INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC

June 25, 2025 | globenewswire.com

Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Assenagon Asset Management S.A.

June 19, 2025 | marketbeat.com

Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?

June 16, 2025 | zacks.com

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of "Hold" from Brokerages

June 15, 2025 | marketbeat.com

3 Reasons to Avoid MYGN and 1 Stock to Buy Instead

June 6, 2025 | msn.com

Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?

June 5, 2025 | zacks.com

Balancing Optimism and Caution: Hold Rating for Myriad Genetics Amid Strategic Shifts and Uncertainties

June 4, 2025 | tipranks.com

Myriad Genetics Shares Higher on Prenatal Screen Update

June 4, 2025 | marketwatch.com

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

June 3, 2025 | globenewswire.com

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

June 2, 2025 | finance.yahoo.com

Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025

May 27, 2025 | insidermonkey.com

Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025

May 27, 2025 | msn.com

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 27, 2025 | globenewswire.com

Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud

May 27, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

May 27, 2025 | accessnewswire.comA

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

May 27, 2025 | finance.yahoo.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

May 26, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN, FOLD, BCRX, and CLDX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.91 -0.05 (-0.51%)

As of 10:34 AM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics NASDAQ:CLDX

$22.51 -0.85 (-3.64%)

As of 10:34 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Amicus Therapeutics NASDAQ:FOLD

$6.02 -0.23 (-3.61%)

As of 10:35 AM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Myriad Genetics NASDAQ:MYGN

$5.18 -0.04 (-0.67%)

As of 10:34 AM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time